01What happened

The story, straight

The FDA reversed its earlier position on uniQure's Huntington's disease gene therapy, clearing the path for the company to file for regulatory approval. UniQure shares jumped 74% on the news. The agency's U-turn comes after it had previously created obstacles to the filing, though the exact nature of those earlier objections is not detailed in the available sources.

FDA flipped on uniQure's Huntington's gene therapy — the company can now file for approval. Stock popped 74%. The agency had apparently blocked the path before, though nobody's spelling out exactly what changed.

02Spread timeline

Where it actually started

Jun 17, 2026Origin
FirstWord Pharma reports the FDA U-turn opens the door to uniQure's Huntington's gene therapy filing.firstword pharma breaks the FDA reversal story
source
Jun 17, 2026
Fierce Biotech reports uniQure stock surging after the FDA clearance.fierce biotech confirms the stock move
source
Jun 17, 2026
Barron's reports the 74% stock surge, characterizing the FDA move as an 'about-face.'barron's calls it an about-face, lands the 74% figure
source

03Source receipts

Every claim, linked

FirstWord PharmaBreaks the story that an FDA regulatory U-turn clears the path to uniQure filing its Huntington's gene therapy
primarygooglenewsreceipt

04What's solid, what isn't

What's solid and what isn't

Confirmed
  • The FDA reversed its earlier position on uniQure's Huntington's disease gene therapy filing.
  • uniQure stock surged approximately 74% on the news.
Disputed
  • The specific reasons behind the FDA's reversal or what data or arguments triggered the change.
  • The exact timeline for uniQure's regulatory filing submission.
Developing
  • Impact on the broader Huntington's treatment pipeline and competing gene therapy programs.

05Why it matters

The editorial take

Huntington's disease has no approved disease-modifying therapies, and gene therapy represents one of the most promising frontiers for treating neurodegenerative conditions. An FDA reversal on a filing pathway signals either new data, changed risk-benefit calculus, or internal regulatory shifts worth watching across the broader gene therapy pipeline.

There's still zero approved treatment that actually slows Huntington's. Gene therapy is the best shot, and a regulatory reversal like this usually means something shifted — new data, new leadership, new risk math. Worth watching for every other gene therapy company too.